Literature DB >> 28947121

Structural imaging in premanifest and manifest Huntington disease.

Rachael I Scahill1, Ralph Andre1, Sarah J Tabrizi2, Elizabeth H Aylward3.   

Abstract

Huntington disease (HD) neuropathology has a devastating effect on brain structure and consequently brain function; neuroimaging provides a means to assess these effects in gene carriers. In this chapter we first outline the unique utility of structural imaging in understanding HD and discuss some of the acquisition and analysis techniques currently available. We review the existing literature to summarize what we know so far about structural brain changes across the spectrum of disease from premanifest through to manifest disease. We then consider how these neuroimaging findings relate to patient function and nonimaging biomarkers, and can be used to predict disease onset. Finally we review the utility of imaging measures for assessment of treatment efficacy in clinical trials.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Huntington disease; MRI; biomarker; cortex; striatum; volumetric; white matter

Mesh:

Year:  2017        PMID: 28947121     DOI: 10.1016/B978-0-12-801893-4.00020-1

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  9 in total

1.  Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.

Authors:  Frederic Sampedro; Saul Martínez-Horta; Jesús Perez-Perez; Andrea Horta-Barba; Diego Alfonso Lopez-Mora; Valle Camacho; Alejandro Fernández-León; Beatriz Gomez-Anson; Ignasi Carrió; Jaime Kulisevsky
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-09       Impact factor: 9.236

2.  Structural neuroimaging differentiates vulnerability from disease manifestation in colombian families with Huntington's disease.

Authors:  Maria Del C Valdés Hernández; Janna Abu-Hussain; Xinyi Qiu; Josef Priller; Mario Parra Rodríguez; Mariana Pino; Sandra Báez; Agustín Ibáñez
Journal:  Brain Behav       Date:  2019-07-05       Impact factor: 2.708

3.  Validating Automated Segmentation Tools in the Assessment of Caudate Atrophy in Huntington's Disease.

Authors:  Nina M Mansoor; Tishok Vanniyasingam; Ian Malone; Nicola Z Hobbs; Elin Rees; Alexandra Durr; Raymund A C Roos; Bernhard Landwehrmeyer; Sarah J Tabrizi; Eileanoir B Johnson; Rachael I Scahill
Journal:  Front Neurol       Date:  2021-04-14       Impact factor: 4.003

Review 4.  Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.

Authors:  Kirsi M Kinnunen; Ariana P Mullin; Dorian Pustina; Emily C Turner; Jackson Burton; Mark F Gordon; Rachael I Scahill; Emily C Gantman; Simon Noble; Klaus Romero; Nellie Georgiou-Karistianis; Adam J Schwarz
Journal:  Front Neurol       Date:  2021-10-22       Impact factor: 4.003

5.  Revealing the Timeline of Structural MRI Changes in Premanifest to Manifest Huntington Disease.

Authors:  Peter A Wijeratne; Sara Garbarino; Sarah Gregory; Eileanoir B Johnson; Rachael I Scahill; Jane S Paulsen; Sarah J Tabrizi; Marco Lorenzi; Daniel C Alexander
Journal:  Neurol Genet       Date:  2021-10-12

Review 6.  Volumetric MRI-Based Biomarkers in Huntington's Disease: An Evidentiary Review.

Authors:  Kirsi M Kinnunen; Adam J Schwarz; Emily C Turner; Dorian Pustina; Emily C Gantman; Mark F Gordon; Richard Joules; Ariana P Mullin; Rachael I Scahill; Nellie Georgiou-Karistianis
Journal:  Front Neurol       Date:  2021-09-21       Impact factor: 4.003

Review 7.  Bilateral lesions of the basal ganglia and thalami (central grey matter)-pictorial review.

Authors:  Sofie Van Cauter; Mariasavina Severino; Rosamaria Ammendola; Brecht Van Berkel; Hrvoje Vavro; Luc van den Hauwe; Zoran Rumboldt
Journal:  Neuroradiology       Date:  2020-08-05       Impact factor: 2.804

8.  Another Perspective on Huntington's Disease: Disease Burden in Family Members and Pre-Manifest HD When Compared to Genotype-Negative Participants from ENROLL-HD.

Authors:  Jannis Achenbach; Carsten Saft
Journal:  Brain Sci       Date:  2021-12-08

Review 9.  The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders.

Authors:  Adam J Schwarz
Journal:  Neurotherapeutics       Date:  2021-04-12       Impact factor: 7.620

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.